Rebus Holdings Inc.
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Market Cap & Net Worth: Rebus Holdings Inc. (RBSH)
Rebus Holdings Inc. (PINK:RBSH) has a market capitalization of $3.21K ($3.21K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #46661 globally and #14519 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rebus Holdings Inc.'s stock price $0.00 by its total outstanding shares 32132907 (32.13 Million).
Rebus Holdings Inc. Market Cap History: 2015 to 2025
Rebus Holdings Inc.'s market capitalization history from 2015 to 2025. Data shows change from $8.40 Trillion to $3.21K (-90.90% CAGR).
Rebus Holdings Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rebus Holdings Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RBSH by Market Capitalization
Companies near Rebus Holdings Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Rebus Holdings Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Rebus Holdings Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, Rebus Holdings Inc.'s market cap moved from $8.40 Trillion to $ 3.21K, with a yearly change of -90.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.21K | 0.00% |
| 2024 | $3.21K | -98.00% |
| 2023 | $160.66K | -33.33% |
| 2022 | $241.00K | -71.80% |
| 2021 | $854.74K | -94.17% |
| 2020 | $14.65 Million | -96.03% |
| 2019 | $368.74 Million | -95.02% |
| 2018 | $7.41 Billion | -83.60% |
| 2017 | $45.19 Billion | -95.45% |
| 2016 | $994.14 Billion | -88.17% |
| 2015 | $8.40 Trillion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Rebus Holdings Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.21K USD |
| MoneyControl | $3.21K USD |
| MarketWatch | $3.21K USD |
| marketcap.company | $3.21K USD |
| Reuters | $3.21K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.